Abstract
English
Highlights
Nonsteroidal anti-inflammatory drugs (NSAIDs), administered rectally, seem to be effective in reducing post-ERCP pancreatitis (PEP)
In clinical practice about 40% of patients undergoing ERCP complain of abdominal pain after the procedure [1]. This may be a consequence of bowel distension, but some studies have shown that it could be an early predictor of post-ERCP pancreatitis (PEP) [2]
The aim of the present study was to assess whether intravenous ketorolac given early as an analgesic to patients with post-procedural abdominal pain lowered the rate of post-ERCP pancreatitis (PEP) in comparison with patients without post-procedural pain who were not given the drug
Summary
Nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g. indomethacin), administered rectally, seem to be effective in reducing post-ERCP pancreatitis (PEP). This effect seems lost with intramuscularly or intravenously administration. Several prospective randomized controlled trials and meta-analyses have shown both diclofenac and indomethacin to be effective for the prevention of PEP [7,8,9,10,11,12] Based on these data recent European guidelines recommend the routine rectal administration of 100 mg of diclofenac or indomethacin in all patients, if there are no contraindications, immediately before or after ERCP to reduce the risk of PEP [8]. A recent randomized controlled trial showed that rectal indomethacin was ineffective for PEP prevention [13]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.